Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma Case report

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: cze 30, 2021
DOI: https://doi.org/10.24292/01.OR.122280621
Słowa kluczowe:
pancreatic adenocarcinoma, liposomal irinotecan, chemotherapy

##plugins.themes.bootstrap3.article.main##

Przemysław Będkowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Department of Daily Chemotherapy, Provincial Hospital in Koszalin
Wojciech Rogowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Pomeranian Academy in Slupsk

Abstrakt

Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.generic.paperbuzz.metrics##

##plugins.generic.paperbuzz.loading##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Będkowski P, Rogowski W. Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma. OncoReview [Internet]. 30 czerwiec 2021 [cytowane 23 lipiec 2024];11(2(42):40-3. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/1444
Numer
Tom 11 Nr 2(42) (2021)
Dział
PERSONALIZED ONCOLOGY
Creative Commons License

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

Bibliografia

1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.02.2021).
2. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.
3. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4(suppl 2): e000818. http://doi.org/10.1136/esmoopen-2020-000818.
4. Charakterystyka produktu leczniczego INN-Paklitaxel.
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25. http://doi.org/10.1056/NEJMoa1011923.